ERBB2 and breast cancer: Emerging evidence indicates that this race-related survival gap is largely due to higher incidence of aggressive subtypes of breast cancer, including basal-like, triple negative, human epidermal growth factor receptor 2 (ERBB2/HER2)-enriched subtypes, which are frequently associated with early metastasis in AA compared to W patients7.